Sequana Medical - A busy H2 coming
No major surprise in this H1 23 update in our view. Good operational progress made in the first half of the year with the publication of two sets of positive results for DSR and the launch of MOJAVE with DSR 2.0. Several catalysts expected in H2. Sequana Medical took the decision to scale back EU commercial activities since the US is the commercial focus. EU is used to assess the performance of the alfapump in a real world setting and train the sales force. OPEX have slightly increased following clinical development progress and preparation of the PMA submission, in line with ourSequana Medical NV. Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.